Agnelli G, Gussoni G, Bianchini C, et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943-949.
Agnelli G, George DJ, Kakkar AK, et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601-609.
Ashrani AA, Gullerud RE, Petterson TM, et al. Risk factors for incident venous thromboembolism in active cancer patients: a population based case-control study. Thromb Res. 2016;139:29-37.
Carrier M, Abou-Nassar K, Mallick R, et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719.
Carrier M, Blais N, Crowther M, et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol. 2018;25:329-337.
Cohen AT, Darmon JY, et al; Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800
Cohen AT, Agnelli G, Anderson FA, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-764.
Cohen AT, Harrington RA, Goldhaber SZ, et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016;375:534-544.
Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513-523.
Rosendaal FR. Causes of venous thrombosis. Thromb J. 2016;14(Suppl 1):24.
Farge D, Frere C, Connors JM, et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566-e581.
Farge D, Frere C. Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. F1000Res. 2019;8:F1000 Faculty Rev-974.
Fernandes CJ, Morinaga LTK, Alves JL Jr, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28:180119
Frere C, Benzidia I, Marjanovic Z, et al. Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges. Cancers (Basel). 2019;11:pii: E71.
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S.
Gerotziafas GT, Taher A, Abdel-Razeq H, et al; COMPASS–CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22:1222-1231.
Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-2177.
Hull RD, Schellong SM, Tapson VF, et al; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8-18.
IMPROVE Inhospital Risk Models. umassmed.org. https://www.outcomes-umassmed.org/IMPROVE/risk_score/index.html. Accessed 10/30/19.
ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12:1580-1590.
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-e226S.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149:315-352.
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019:JCO1901461. doi: 10.1200/JCO.19.01461. [Epub ahead of print]
Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632-634.
Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;15;111:4902-4907.
Khorana AA, Soff GA, Kakkar AK, et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720-728.
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society. Eur Heart J. 2019. doi: 10.1093/eurheartj/ehz405. [Epub ahead of print]
Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-686.
Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
Mahan CE, Burnett AE, Fletcher ML, et al. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis. Hosp Pract (1995). 2018;46:5-15.
Navi BB et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781.
Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-2348.
Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624.
Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2:3198-3225.
Spyropoulos AC, Ageno W, Albers GW, et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379:1118-1127.
Stubbs JM, Assareh H, Curnow J, et al. Incidence of in‐hospital and post‐discharge diagnosed hospital‐associated venous thromboembolism using linked administrative data. Intern Med J. 2018;48:157-165.
Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE

Professor of Surgery, University College London
Chairman of University College London Partners Academic Health Science Partnership
Director of the Thrombosis Research Institute, London, United Kingdom

Disclosures

Disclosure: Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Boehringer-Ingelhiem; Daiichi Sankyo Europe; Janssen; Pfizer; Sanofi; Verseon
Received grants for clinical research from: Bayer AG

Gregoire Le Gal, MD, PhD

Professor, Division of Hematology
Department of Medicine,
University of Ottawa
Ottawa, Canada

Disclosures

Disclosure: Gregoire Le Gal, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb; Pfizer; Sanofi
Served as a speaker or a member of a speakers bureau for: Bayer AG; BioMerieux; LEO Pharma; Pfizer; Sanofi
Received grants for clinical research from: Boehringer-Ingelheim; Pfizer; Portola Pharmaceuticals
Owns stock, stock options, or bonds from: Bristol-Myers Squibb; Bayer AG; Daiichi Sankyo; LEO Pharma

Benjamin Brenner, MD

Professor of Hematology
Rambam Health Care Campus
Caster Chair of Leukemia Research
Bruce Rappaport Faculty of Medicine
Technion, Israel Institute of Technology
Haifa, Israel

Disclosures

Disclosure: Benjamin Brenner, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Pfizer; Sanofi
Served as a speaker or a member of a speakers bureau for: Bayer AG; Pfizer; ROVI; Sanofi

Ismail Elalamy, MD

Professor of Hematology
Director of Hematology Department
of Thrombosis Center
CHU Tenon
Paris, France

Disclosures

Disclosure: Ismail Elalamy, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aspen Pharmacare; Bayer HealthCare; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Leo Pharma; Pfizer Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Aspen Pharmacare; Bayer HealthCare; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Leo Pharma; Pfizer Inc.; Sanofi; Stago
Received grants for clinical research from: Aspen Pharmacare; Leo Pharma; Stago

Editor

Philippa Berman, BA (Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa Berman, BA (Hons), MBBS, has disclosed no relevant financial relationships.

Robert McCarthy, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

CPD

Management of Venous Thrombosis: From Evidence to Clinical Practice

Authors: Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE; Gregoire Le Gal, MD, PhD; Benjamin Brenner, MD; Ismail Elalamy, MD
CPD Released: 2/26/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 2/26/2021

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US cardiologists, hematology-oncology specialists, and primary care physicians involved in the prevention of VTE in patients with acute medical illness or cancer.

To increase clinicians’ knowledge of current guidelines and clinical trial data related to prevention of VTE in patients with acute medical illness or cancer.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Guideline-recommended therapy and trial data in prevention of venous thromboembolism (VTE) in acutely ill medical patients
- Guideline-recommended therapy and trial data in prevention of VTE in patients with cancer
Have increased confidence regarding the selection of antithrombotic therapy to prevent VTE in acutely ill medical patients and patients with cancer

Disclosures

Faculty

Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE

Professor of Surgery, University College London
Chairman of University College London Partners Academic Health Science Partnership
Director of the Thrombosis Research Institute, London, United Kingdom

Disclosures

Disclosure: Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Boehringer-Ingelhiem; Daiichi Sankyo Europe; Janssen; Pfizer; Sanofi; Verseon
Received grants for clinical research from: Bayer AG

Gregoire Le Gal, MD, PhD

Professor, Division of Hematology
Department of Medicine,
University of Ottawa
Ottawa, Canada

Disclosures

Disclosure: Gregoire Le Gal, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb; Pfizer; Sanofi
Served as a speaker or a member of a speakers bureau for: Bayer AG; BioMerieux; LEO Pharma; Pfizer; Sanofi
Received grants for clinical research from: Boehringer-Ingelheim; Pfizer; Portola Pharmaceuticals
Owns stock, stock options, or bonds from: Bristol-Myers Squibb; Bayer AG; Daiichi Sankyo; LEO Pharma

Benjamin Brenner, MD

Professor of Hematology
Rambam Health Care Campus
Caster Chair of Leukemia Research
Bruce Rappaport Faculty of Medicine
Technion, Israel Institute of Technology
Haifa, Israel

Disclosures

Disclosure: Benjamin Brenner, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Pfizer; Sanofi
Served as a speaker or a member of a speakers bureau for: Bayer AG; Pfizer; ROVI; Sanofi

Ismail Elalamy, MD

Professor of Hematology
Director of Hematology Department
of Thrombosis Center
CHU Tenon
Paris, France

Disclosures

Disclosure: Ismail Elalamy, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aspen Pharmacare; Bayer HealthCare; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Leo Pharma; Pfizer Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Aspen Pharmacare; Bayer HealthCare; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Leo Pharma; Pfizer Inc.; Sanofi; Stago
Received grants for clinical research from: Aspen Pharmacare; Leo Pharma; Stago

Editor

Philippa Berman, BA (Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa Berman, BA (Hons), MBBS, has disclosed no relevant financial relationships.

Robert McCarthy, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Management of Venous Thrombosis: From Evidence to Clinical Practice

Authors: Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE; Gregoire Le Gal, MD, PhD; Benjamin Brenner, MD; Ismail Elalamy, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 2/26/2020

Valid for credit through: 2/26/2021

processing....

Legendas em português

« Return to: Management of Venous Thrombosis: From Evidence to Clinical Practice

Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE

Gregoire Le Gal, MD, PhD

Benjamin Brenner, MD

Ismail Elalamy, MD

Editor

Philippa Berman, BA (Hons), MBBS

Robert McCarthy, PhD

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

CPD

Management of Venous Thrombosis: From Evidence to Clinical Practice

Target Audience and Goal Statement

Disclosures

Faculty

Ajay Kakkar, BSc, MBBS, PhD, FRCS, FRCPE

Gregoire Le Gal, MD, PhD

Benjamin Brenner, MD

Ismail Elalamy, MD

Editor

Philippa Berman, BA (Hons), MBBS

Robert McCarthy, PhD

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Management of Venous Thrombosis: From Evidence to Clinical Practice

Legendas em português